Lincoln Pharmaceuticals Limited has informed the Exchange about Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has submitted a routine quarterly compliance certificate to NSE and BSE for the quarter ended June 30, 2025. The certificate, issued by their Registrar and Share Transfer Agent (MUFG Intime India Private Limited), confirms that all share dematerialisation requests received during the quarter were properly processed and confirmed to the depositories. It also confirms that physical share certificates received for demat were mutilated and cancelled, and the depository's name was substituted as the registered owner in the company's member register within the prescribed timelines. No specific numbers, counts, or rejected requests are disclosed in the filing. This is a standard procedural submission required under SEBI regulations and carries no business or financial information.
No impact on shareholders or stock price. This is a routine regulatory compliance filing confirming the proper handling of share dematerialisation requests for Q1 FY26 — investors should treat it as administrative housekeeping only.